S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,255.31 (+0.13%)
DOW   39,786.30 (+0.07%)
QQQ   445.52 (+0.16%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.83 (-11.75%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)

4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis

$33.02
-2.85 (-7.95%)
(As of 09:47 AM ET)
Today's Range
$32.53
$34.20
50-Day Range
$17.03
$35.87
52-Week Range
$9.44
$36.25
Volume
125,590 shs
Average Volume
1.15 million shs
Market Capitalization
$1.64 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.44

4D Molecular Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
10.0% Upside
$39.44 Price Target
Short Interest
Bearish
17.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of 4D Molecular Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$15.04 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.97) to ($3.76) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.38 out of 5 stars

Medical Sector

902nd out of 939 stocks

Biological Products, Except Diagnostic Industry

153rd out of 157 stocks

FDMT stock logo

About 4D Molecular Therapeutics Stock (NASDAQ:FDMT)

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

FDMT Stock Price History

FDMT Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
4DMT to Participate in Upcoming Investor Conferences
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
4DMT Secures FDA RPDD For Aerosolized 4D-710
See More Headlines
Receive FDMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FDMT
Fax
N/A
Employees
147
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.44
High Stock Price Target
$81.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+10.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$-100,840,000.00
Net Margins
-436.30%
Pretax Margin
-486.60%

Debt

Sales & Book Value

Annual Sales
$20.72 million
Book Value
$7.20 per share

Miscellaneous

Free Float
44,452,000
Market Cap
$1.79 billion
Optionable
Optionable
Beta
2.86
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. John F. Milligan Ph.D. (Age 63)
    Executive Chairman
    Comp: $150k
  • Dr. David H. Kirn M.D. (Age 62)
    Co-Founder, CEO & Director
    Comp: $920.97k
  • Dr. Fariborz Kamal Ph.D. (Age 61)
    President & COO
    Comp: $678.4k
  • Dr. Noriyuki Kasahara M.D. (Age 61)
    Ph.D., Chief Scientific Officer
    Comp: $13.6k
  • Ms. Theresa Janke (Age 49)
    Co-Founder & Chief of Staff
    Comp: $652.32k
  • Mr. Uneek Mehra (Age 52)
    Chief Financial & Business Officer
  • Dr. Scott P. Bizily J.D. (Age 51)
    Ph.D., Chief Legal Officer & Corporate Secretary
  • Dr. Robert Y. Kim M.B.A. (Age 63)
    M.D., Chief Medical Officer
  • Dr. An Song Ph.D.
    Chief Development Officer
  • Dr. Alan H. Cohen FAAAAI (Age 63)
    FAAP, FACAAI, FCCP, M.D., Senior VP & Therapeutic Area Head of Pulmonology

FDMT Stock Analysis - Frequently Asked Questions

Should I buy or sell 4D Molecular Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FDMT shares.
View FDMT analyst ratings
or view top-rated stocks.

What is 4D Molecular Therapeutics' stock price target for 2024?

9 analysts have issued 1 year price targets for 4D Molecular Therapeutics' shares. Their FDMT share price targets range from $13.00 to $81.00. On average, they expect the company's stock price to reach $39.44 in the next twelve months. This suggests a possible upside of 10.0% from the stock's current price.
View analysts price targets for FDMT
or view top-rated stocks among Wall Street analysts.

How have FDMT shares performed in 2024?

4D Molecular Therapeutics' stock was trading at $20.26 on January 1st, 2024. Since then, FDMT stock has increased by 77.0% and is now trading at $35.87.
View the best growth stocks for 2024 here
.

When is 4D Molecular Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our FDMT earnings forecast
.

How were 4D Molecular Therapeutics' earnings last quarter?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) issued its quarterly earnings results on Thursday, February, 29th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.09. The firm earned ($0.02) million during the quarter, compared to analysts' expectations of $4.67 million. 4D Molecular Therapeutics had a negative trailing twelve-month return on equity of 34.14% and a negative net margin of 436.30%.

What ETFs hold 4D Molecular Therapeutics' stock?

ETFs with the largest weight of 4D Molecular Therapeutics (NASDAQ:FDMT) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

When did 4D Molecular Therapeutics IPO?

4D Molecular Therapeutics (FDMT) raised $101 million in an initial public offering on Friday, December 11th 2020. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair acted as the underwriters for the IPO and Chardan was co-manager.

Who are 4D Molecular Therapeutics' major shareholders?

4D Molecular Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.37%), Vanguard Group Inc. (3.75%), Novo Holdings A S (3.51%), Goldman Sachs Group Inc. (1.91%), Goldman Sachs Group Inc. (1.91%) and Dimensional Fund Advisors LP (1.63%). Insiders that own company stock include David Kirn, David Schaffer, Global Investors Lp Viking, Jacob Chacko, Robert Young Kim and Scott Bizily.
View institutional ownership trends
.

How do I buy shares of 4D Molecular Therapeutics?

Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FDMT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners